Cabaletta Bio, Inc. (CABA)
| Market Cap | 342.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.43M |
| Shares Out | 24.04M |
| EPS (ttm) | -10.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $14.22 |
| Previous Close | $12.76 |
| Change ($) | 1.46 |
| Change (%) | 11.44% |
| Day's Open | 12.71 |
| Day's Range | 12.61 - 14.72 |
| Day's Volume | 174,023 |
| 52-Week Range | 6.00 - 18.67 |
Cabaletta Bio, Inc. is a clinical-stage biotechnology company aiming to develop engineered T-cell therapies for B-cell-mediated autoimmune diseases. Cabaletta has 3 potential therapeutics from...
First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoi...
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapi...
PHILADELPHIA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapi...
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell ther...
PHILADELPHIA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell thera...
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell thera...
PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T...
Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases
PHILADELPHIA, May 12, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therap...
Cabaletta Bio: Curative Medicines For Autoimmunity
Cabaletta Bio, Inc. (CABA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Cabaletta Bio Inc. shares slid 18% in their trading debut Friday, after underwriters priced the deal at $11, a full $3 below the $14 to $16 price range.
About CABA
Cabaletta Bio, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blister... [Read more...]
| Industry Biotechnology | IPO Date Oct 25, 2019 |
| CEO Dr. Steven A. Nichtberger | Employees 31 |
| Stock Exchange NASDAQ | Ticker Symbol CABA |
Analyst Forecasts
According to 5 analysts, the average rating for Cabaletta Bio stock is "Strong Buy." The 12-month stock price forecast is 20.33, which is an increase of 42.97% from the latest price.